Internal Medicine, Hematology & Oncology · Vineland, NJ
NPI
1508898594
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
1505 W Sherman Ave, Suite 101
Vineland, NJ, 08360
Phone (856) 696-9550
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
114,596 services
Medicare patients, 2024
617
Average age 75
Drug cost, 2024
$6.1M
1,561 prescriptions
Company payments, 2025
$2,451
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shailja Roy was code J1439 (injection, ferric carboxymaltose, 1 mg), 40,500 times for 33 patients. In total Shailja Roy billed 114,596 services in 97 codes, and Medicare paid $1.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 40,500 | 33 | $0.86 | $35K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,200 | 11 | $44.67 | $322K |
| J0897 Injection, denosumab, 1 mg | Office | 6,060 | 25 | $20.23 | $123K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 5,550 | 11 | $0.11 | $611 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 5,148 | 14 | $20.75 | $107K |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 1,470 | 11 | $45.98 | $68K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,346 | 38 | $0.10 | $129 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 810 | 25 | $0.81 | $659 |
| 85025 Blood Count | Office | 756 | 292 | $7.58 | $5,731 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 504 | 15 | $0.07 | $37.27 |
| 99213 Office E&M - Established | Office | 438 | 266 | $72.91 | $32K |
| 99214 Office E&M - Established | Office | 372 | 176 | $109.82 | $41K |
| 96375 Injection Administration | Office | 298 | 44 | $13.78 | $4,106 |
| 96372 Injection Administration | Office | 244 | 73 | $12.48 | $3,046 |
| 96413 Chemotherapy Administration | Office | 182 | 58 | $118.07 | $21K |
By year: 2022 $1.6M for 136,832 services; 2023 $1.9M for 166,472 services; 2024 $1.4M for 114,596 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 756 | 292 | $7.58 | $5,731 |
| 80053 Clinical Chemistry | 44 | 19 | $10.35 | $455 |
| 81003 Clinical Chemistry | 22 | 11 | $2.20 | $48.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Shailja Roy prescribed most often to Medicare patients was Anastrozole, with 155 prescriptions and refills. In total Shailja Roy wrote 1,561 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 155 | 439 | 50 | $4,300 |
| Letrozole Generic | 96 | 262 | 36 | $2,502 |
| Ibrance Palbociclib | 81 | 81 | 14 | $1.2M |
| Eliquis Apixaban | 60 | 96 | 19 | $55K |
| Keytruda Pembrolizumab | 53 | 53 | Under 11 | $598K |
| Procrit Epoetin Alfa | 46 | 48 | Under 11 | $53K |
| Oxycodone Hcl Generic | 40 | 40 | 19 | $667 |
| Alendronate Sodium Generic | 39 | 55 | Under 11 | $243 |
| Xgeva Denosumab | 35 | 44 | Under 11 | $113K |
| Dexamethasone Sodium Phosphate Generic | 31 | 31 | Under 11 | $58.57 |
| Exemestane Generic | 31 | 90 | Under 11 | $3,979 |
| Hydroxyurea Generic | 30 | 56 | Under 11 | $714 |
| Imatinib Mesylate Generic | 28 | 28 | Under 11 | $2,426 |
| Prednisone Generic | 26 | 32 | 13 | $142 |
| Venclexta Venetoclax | 26 | 26 | Under 11 | $200K |
Brand drugs: 609 claims; generic drugs: 952 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shailja Roy $2,451 ($2,451 in general payments such as food, travel and fees) from 42 companies. The largest payer was GlaxoSmithKline, LLC. with $225.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 13 | $225 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $222 |
| Daiichi Sankyo Inc. 4568.T | 10 | $219 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $183 |
| Astellas Pharma US Inc 4503.T | 5 | $103 |
| Abbvie Inc. ABBV | 6 | $93.51 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $92.12 |
| Incyte Corporation INCY | 5 | $84.68 |
| Merck Sharp & Dohme LLC MRK | 4 | $81.65 |
| Array Biopharma Inc PFE | 5 | $78.19 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.